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Abstract
The precise aetiology of systemic sclerosis (SSc) remains elusive,
but significant advances over the past few years have improved our
understanding of the underlying pathogenic processes and
identified key pathways and mediators that are potential
therapeutic targets. The situation is complicated by the clinical
heterogeneity of SSc and the differential pathogenesis that
underlies the two commonest subsets, namely diffuse and limited
cutaneous disease. However, there are common mediators that
could be targeted to provide clinical benefit in both types of
disease. To date, clinical success with therapies directed against
logical profibrotic mediators, such as connective tissue growth
factor and transforming growth factor-β, is yet to be reported,
although studies are ongoing. More promising clinical results have
been obtained with the dual endothelin receptor antagonist
bosentan, which has been shown to manage two vascular
complications of SSc effectively: pulmonary arterial hypertension
and digital ulceration. It remains to be determined whether the
identification of additional mediators merely furthers our knowledge
of the natural history of SSc or presents targets that can be
manipulated to manage SSc patients effectively.
Introduction
Ongoing studies of the pathogenesis of systemic sclerosis
(SSc) have yielded improved understanding of the complex
cellular interactions that occur in this heterogeneous
connective tissue disease. It is clear from studies of lesional
skin in SSc that there is a common sequence of pathogenic
events. This sequence starts with microvascular change,
including endothelial cell activation, which is followed by
inflammation and immune cell activation, with a perivascular
infiltration of inflammatory cells initially from the innate
immune system and including cells of the monocyte/
macrophage lineage. Later, there is evidence of involvement
of the adaptive immune system. Lymphocytic infiltrates are
noted, including T cells bearing markers of activation. Recent
studies have also identified B-cell genetic signature as a
hallmark feature of SSc skin. As the disease progresses there
is evidence of a profibrotic fibroblastic cell population
becoming established within the skin. This leads to increased
extracellular matrix deposition. Early studies showed that
these profibrotic cells are initially located around blood
vessels but that later they are more generally distributed. As
the disease becomes well established lesional skin becomes
relatively avascular, and after 12 to 18 months there is often
little evidence of ongoing inflammation. This suggests that
there are probably distinct phases, at least in the skin, when
the component processes of SSc might be amenable to
therapeutic modulation [1]. Thus, targeted therapy is likely to
depend critically on disease stage and subset.
Differential pathogenesis in subsets of
systemic sclerosis
The clinical heterogeneity of SSc makes it likely that different
pathogenic processes operate in different disease subsets.
Diffuse cutaneous SSc (dcSSc) has a much more inflam-
matory onset than does limited cutaneous disease (lcSSc).
There is often widespread inflammation in the skin and
musculoskeletal system, and oedema suggestive of altered
endothelial permeability. Later in the course of disease,
extensive fibrotic changes are apparent. Atrophy in the late
stages may be more consequential than fibrosis. The dynamic
nature of the process is highlighted by the frequent
regression of skin disease at later stages, which can account
for the observed apparent spontaneous fall in skin sclerosis
score in dcSSc over time. Raynaud’s symptoms generally
occur contemporaneously with skin changes in dcSSc, or
they may even occur afterward. This can delay diagnosis and
broaden the differential diagnosis in early stage dcSSc.
In contrast, lcSSc has a much slower onset. Raynaud’s
phenomenon may pre-exist for several years. In this subset of
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disease, the vascular component of SSc is much more
prominent and is responsible for many of the clinical
manifestations of the disease, including pulmonary arterial
hypertension (PAH), digital ulceration and scleroderma renal
crises. However, some degree of fibrosis is always present,
including sclerosis of skin in the face and extremities and
within the gastrointestinal tract, leading to the universal
presence of gastro-oesophageal reflux.
Intercellular interactions in systemic sclerosis
It seems likely that there is a complex interaction between
multiple cell types during the evolution of SSc. These cell
types may interact through direct contact, but soluble
mediators are also likely to be critical. These regulate cell
migration, differentiation and proliferation. Cellular origins may
be diverse within lesional tissue, and there has been a recent
focus on the role of progenitor cells locally or migrating from
other sites, such as bone marrow or from peripheral blood.
The myofibroblast is the effector cell for fibrosis and many
other organ-based changes. Myofibroblasts are likely to be
derived from at least three sources: local fibroblasts,
transdifferentiation and other cell types. Circulating and
locally produced soluble mediators regulate this process. The
key patterns of intercellular interaction that operate in SSc
pathogenesis are summarized in Figure 1.
Cellular mediators in systemic sclerosis as
potential therapeutic targets
Transforming growth factor-β β
Descriptive studies of SSc, including examination of
explanted skin fibroblasts and gene and protein profiling
studies, implicate a number of growth factors or cytokines in
SSc. A consistent candidate mediator is transforming growth
factor (TGF)-β. This has potent profibrotic activity in vitro and
stimulates myofibroblast differentiation. A number of studies
have demonstrated increased TGF-β ligand expression in
lesional SSc skin, and altered downstream signalling has
been reported in SSc fibroblasts, although the data are
somewhat conflicting.
Surprisingly, circulating levels of active TGF-β1 are reduced in
patients with dcSSc compared with healthy control individuals
or patients with lcSSc [2]. In addition, there is an inverse
relationship between TGF-β1 in the circulation and skin score,
and a correlation with disease duration. This may be explained
by sequestration of active TGF-β in lesional tissues such as
the skin caused by upregulation of various TGF-β binding
proteins, many of which are TGF-β inducible. There is
evidence to support this from gene profiling studies [3]. Total
levels of ligand are not suppressed in SSc. When skin is
examined directly there is evidence of increased TGF-β1 and
Figure 1
Cellular interactions in pathogenesis of SSc. The multiple cell types implicated in pathogenesis of SSc are illustrated. Soluble mediators involved in
this intercellular cross-talk are candidate targets for therapeutic intervention. bFGF, basic fibroblast growth factor; CTGF, connective tissue growth
factor; EC, endothelial cell; ECM, extracellular matrix; ET, endothelin; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein;
PDGF, platelet-derived growth factor; SMA, smooth muscle actin; SSc, systemic sclerosis; TGF, transforming growth factor; TH, T-helper (cell);
Treg, regulatory T (cell); VEGF, vascular endothelial growth factor. Reproduced with permission from [1]. Page 3 of 5
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TGF-β2 mRNA in skin biopsies in both involved and uninvolved
skin compared with the skin of healthy control individuals.
Evidence for direct involvement of TGF-β activation in
fibroblasts comes from mouse models, in which selective
activation of TGF-β signalling was observed in fibroblasts but
not in other cell types. This has been demonstrated in two
mouse models. In the first there is expression of a non-
signalling human type II TGF-β receptor in fibroblasts using
an expression cassette subcloned from the type I collagen
gene Col1a2 [4,5]. This mouse exhibits constitutive ligand-
dependent activation of TGF-β genes in skin and other
organs, and the animals develop skin fibrosis reminiscent of
scleroderma. Interestingly, they also appear to be susceptible
to organ-based fibrosis such as lung disease, although this
may require additional triggers such as epithelial cell injury.
Fibroblasts from the skin of TβRII∆k-fib mice closely resemble
those from SSc skin, exhibiting myofibroblast differentiation,
TGF-β activation, and over-expression of connective tissue
growth factor (CTGF) and plasminogen activator inhibitor-1
on gene profiling. These animals provide a valuable platform
for testing targeted therapy, and blocking TGF-β signalling
attenuated the scleroderma-like phenotype, as expected.
In the second, related mouse model, a Cre-Lox strategy has
been used to induce genetic recombination postnatally. In
this way, a constitutively active TGF-β type I receptor can be
activated, and this model develops even more severe skin
changes and a generalized vasculopathy reminiscent of
scleroderma. Together, these mouse strains make it highly
plausible that sustained activation of TGF-β signalling in
fibroblasts can induce the hallmark features of SSc.
Scleroderma fibroblasts can be explanted, and recent studies
have confirmed that blocking activin-like kinase receptor 5,
the TGF-β type I receptor that is active in the inducible mouse
strain, attenuates some of the hallmark biochemical features
of SSc fibroblasts. Interestingly, some features cannot be
reversed, including CTGF over-expression, which is in
contrast to the mouse models and suggests that other
mediators must also be important in human SSc [6].
To test fully the role of TGF-β signalling, a mouse strain has
been generated in which the TGF-β type II receptor is deleted
postnatally. These animals are resistant to lung fibrosis and
do not form fibrous scars in healing skin wounds or contract
skin wounds appropriately. However, they develop digital
contractures that are reminiscent of scleroderma. This raises
the hypothesis that although TGF-β overactivity may be a key
to early SSc, reduced responsiveness may operate later.
Connective tissue growth factor
Although a logical target, TGF-β blockade is potentially
problematic. There are real concerns about safety, including
potential hazards of neoplasia and immune cell activation.
Other molecules may be more appropriate targets. One such
molecule is CTGF [7]. A member of the CCN family, CTGF
(also known as CCN2) is a protein that has consistently been
shown to be over-expressed in SSc. It may have direct
profibrotic activity, but it also plays a key role in promoting
cell adhesion and other aspects of the SSc phenotype. Other
CCN family members are also implicated in fibrosis. Studies
of CTGF serum and blister fluid levels suggest a correlation
with skin sclerosis score. It is likely that CTGF represents a
valuable marker of the fibrotic process in SSc, and soluble
levels of the amino-terminal portion may be a useful surrogate
for fibrotic burden [8].
Endothelium-derived mediators
Mediators that are produced by endothelial cells are
especially interesting, considering the early events in SSc
pathogenesis. Experimental systems have identified candi-
date mediators, and these include chemokines such as CC
chemokine ligand (CCL)2 and CCL7 [9,10]. Both were
recently shown to be elevated in SSc. CCL2 elevation
appears to be associated with disease severity, and high
levels of CCL2 are found in patients with major internal organ
involvement in early dcSSc. CCL2 may have potential as a
mediator that promotes migration, transdifferentiation and
matrix production by myofibroblasts in SSc. Recent studies
have confirmed that a subgroup of early dcSSc fibroblasts
expresses the CCL2 receptor, and so the potential for
autocrine or paracrine stimulation of fibroblasts in SSc is
clear. In vitro experiments support this.
Endothelin (ET)-1 is a prototypic endothelial cell (EC)-derived
product that possesses many of the hallmark properties that
could be relevant to pathogenesis in SSc. This supposition
comes from studies examining the production of these
cytokines. ET-1 is a peptide that was first identified as an EC
product. Levels of ET-1 released by ECs in monolayer culture
are impressive, particularly considering the potential for this
factor to link vascular inflammatory and fibrotic processes.
Experimental data confirm over-expression of ET-1 peptide by
three EC lines in tissue culture and that ET-1 promotes
contraction and remodelling of fibroblast-populated collagen
lattices, an established model for fibrosis [11]. ET-1 can
induce myofibroblast differentiation in SSc, and blocking ET-
1 using the dual endothelin receptor antagonist (endothelin
receptor subtype A [ETA]/ETB) bosentan has been shown to
reduce α-smooth muscle actin expression by lung fibroblasts
cultured from SSc biopsies [12]. Gene expression profiles of
lung fibroblasts treated with ET-1 are similar to those seen in
SSc and can be normalized by bosentan. This provides some
of the strongest data ex vivo for a role for autocrine ET-1
production as a driver of fibrosis. The validity of targeting
ET-1 in SSc is confirmed by studies demonstrating that
bosentan is an effective treatment for SSc-associated PAH
[13] as well as for ischaemic digital ulceration [14]. Other
endothelin receptor blocking drugs are being developed.
Sitaxentan is an ETA-specific antagonist that is now licensed
in Europe for treatment of PAH. Broader beneficial effects of
Available online http://arthritis-research.com/content/9/S2/S6this agent have not yet been explored. Another single ETA-
receptor antagonist, ambrisentan, has recently been approved
in the US. The significance of dual versus ETA-specific
antagonism in the clinical arena remains to be elucidated.
Nitric oxide is an important mediator that has proinflammatory
effects at high levels and is an important mediator of endo-
thelium-dependent vasodilatation. The effects of nitric oxide are
mediated via cGMP, and levels of this second messenger are
increased when the degradative enzyme phosphodiesterase V
is inhibited. This mechanism underlies the beneficial effect of
agents such as sildenafil in treatment of PAH complicating SSc.
Platelet-derived growth factor
Pericytes may be important in the development of fibrosis by
transdifferentiation into fibroblasts or myofibroblasts. This
process may be intrinsic to wound healing and is regulated
by platelet-derived growth factor. Its importance in organ-
based fibrosis is unclear, but in the skin recent studies have
clearly shown that platelet-derived growth factor signalling is
critical to pericyte activation and that this sequence occurs as
SSc progresses [15].
Therapeutic intervention: targeting pathways
or mediators
The many mediators that have been implicated in SSc
pathogenesis, and especially in fibroblast activation, are likely
to signal via convergent signalling pathways intracellularly.
This may include common signalling intermediates and
modulation of likely transcription factors that regulate gene
expression [16]. Whether these convergent pathways could
be targeted for therapy depends on their involvement in other
cellular processes and on whether there can be selective
attention in disease states. At present this seems unlikely,
and major concern about pathway directed drugs remains.
It is more likely that ligand-directed strategies will be
effective, and this is certainly the case for many other
diseases, including inflammatory arthritis. Cross-talk between
mediators must be considered and it is possible that multiple
proteins will need to be targeted either sequentially or
together. It is very encouraging that there is a growing
armamentarium of potential ligand-directed antagonists, some
of which are listed in Table 1. Some of these agents have
already been evaluated in fibrotic disease, and although none
has yet been found to be effective, early-stage proof of
concept studies are being developed. In a safety study of
human anti-TGF-β1 there was no evidence of a treatment
effect, but the treatment did not appear to be toxic [17].
Further evaluation of a pan-specific anti-TGF-β agent in
idiopathic lung fibrosis is ongoing.
It is encouraging that one of these strategies, namely
endothelin blockade, has already been shown to be effective
in treating two major complications of SSc. Studies in lung
fibrosis complicating SSc were unable to demonstrate
efficacy, but this may reflect disease progression and trial
design rather than lack of antifibrotic potential. It is very
tempting to speculate that blocking a mediator such as ET-1
would be a valuable strategy in treating SSc, and the fact that -
for the first time - a manifestation of the disease can be
prevented (digital ulceration) is a major finding. In addition,
the fact that several of the agents listed in Table 1 have
acceptable safety profiles makes evaluation in SSc of their
impact on advanced clinical outcomes imperative.
Conclusion
Substantial advances have been made in elucidating the
pathogenesis of SSc, which has been facilitated in part by
the development of more appropriate animal models.
Targeting of several putative mediators is now feasible [16].
Convergence of signalling pathways suggests synergy
between antagonists. A hierarchy of mediators may
determine stage-specific efficacy. It remains to be deter-
mined whether these exciting strategies only inform about
disease processes or confer real therapeutic advantage. A
key question, however, is whether targeted therapies will
ultimately prove to be more effective than broader approa-
ches, such as high-dose immunosuppression. Ongoing trials
of immunosuppression with cyclophosphamide and haemo-
poietic stem cell transplantation are important studies that
will better define the benefit of these treatments in early-
stage dcSSc [18].
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Table 1
Attenuation of key pathways in systemic sclerosis: agents for
evaluation
Candidate therapy Target pathway
Bosentan ETA/ETB pathway
Imatinib PDGF receptor signalling
Infliximab TNF-α
Adalimumab TNF-α
Etanercept TNF-α
CAT-192 TGF-β1
GC-1008 TGF-β1, TGF-β2, TGF-β3
FG-3019 CTGF ligand
Alefacept LFA3/CD2
Basiliximab IL-2Rα
MLM-1202 CCR2
Efalizumab LFA/ICAM-1
CCR, CC chemokine receptor; ETA/B, endothelin receptor subtype
A/B; CTGF, connective tissue growth factor; ICAM, intercellular
adhesion molecule; IL-2Rα, interleukin-2 receptor α; LFA, lymphocyte
function associated; PDGF, platelet-derived growth factor; TGF,
transforming growth factor; TNF, tumour necrosis factor.Acknowledgements
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